GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (OTCPK:ALPMY) » Definitions » Valuation Rank

Astellas Pharma (Astellas Pharma) Valuation Rank


View and export this data going back to 2008. Start your Free Trial

What is Astellas Pharma Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Astellas Pharma Valuation Rank Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Astellas Pharma (Astellas Pharma) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (OTCPK:ALPMY) » Definitions » Valuation Rank
Comparable Companies
TSE:4578 TSE:4151 TSE:4528 TSE:4536 TSE:4552 TSE:4882 TSE:4568 TSE:4519 LLY JNJ MRK ABBV XSWX:ROG LSE:AZN XSWX:NOVN PFE AMGN XPAR:SAN BMY GILD
Traded in Other Exchanges
ALPMF:USA 4503:Mexico 4503:Japan YPHA:Germany
Address
2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Website
http://www.astellas.com
Astellas Pharma Inc is a drug manufacturing company that sells pharmaceutical products across the globe. The vast majority of the company's revenue is derived from Japanese markets, followed by the Americas. Royalty income makes up a small percentage of Astellas' overall sales. Its largest therapeutic area by sales composition is oncology, followed by urology and transplantation. The company uses mergers and acquisitions as part of its long-term growth strategy. Astellas enters into strategic partnerships and licensing agreements to strengthen its commercialization platforms.